Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.63 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.63 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ITGAM | P11215 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090791 | 0.82 | ITGB3 (0.89) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL5144246 | 0.79 | ITGB3 (0.57) | ITGB3ITGA2B | |
| SCHEMBL12556120 | 0.71 | MIF (0.65) | ITGB3ITGA2B | |
| SCHEMBL7536624 | 0.71 | MIF (0.45) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7375254 | 0.71 | MIF (0.47) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL14189256 | 0.70 | MIF (0.63) | ITGB3ITGA2B | |
| SCHEMBL12517811 | 0.69 | ITGB3 (0.70) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL12555488 | 0.69 | MIF (0.68) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL12556240 | 0.69 | MIF (0.74) | ITGB3ITGA2BITGB2ITGAM | |
| SCHEMBL7525564 | 0.69 | MIF (0.42) | ITGB3ITGA2BITGB2ITGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | FGB, SELPLG, SELL | ITGB3 40/4885ITGA2B 18/4885ITGB2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.